Sangamo's stock jumps after upbeat trial data for hemophilia treatment

Shares of Sangamo Therapeutics Inc. SGMO, -0.10% shot up 7.9% in premarket trade Tuesday, after the genomic medicine company and Pfizer Inc. PFE, +0.87% announced “encouraging” results from a phase 1/2 study of SB-525 gene therapy for the treatment of severe hemophilia A. Pfizer’s stock was still inactive ahead of the open. The companies said SB-525 was generally well tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts. Based on the study’s results, the Safety Monitoring Committee (SMC) recommended expansion at a specific dose. “These interim results suggest that SB-525 may be well-tolerated and may prove to have the predictability and sustained treatment effect that can bring clinical benefit in patients with hemophilia A,” said Sangamo Chief Medical Officer Edward Conner. Sangamo’s stock has tumbled 17.0% year to date through Monday and Pfizer shares have slipped 1.9%, while the Dow Jones Industrial Average DJIA, +1.27% has climbed 12.6%.

Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.

Read More Here...

Bookmark the permalink.